These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35792553)

  • 1. Controlled variable selection in Weibull mixture cure models for high-dimensional data.
    Fu H; Nicolet D; Mrózek K; Stone RM; Eisfeld AK; Byrd JC; Archer KJ
    Stat Med; 2022 Sep; 41(22):4340-4366. PubMed ID: 35792553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
    Muresan B; Mamolo C; Cappelleri JC; Mokgokong R; Palaka A; Soikkeli F; Heeg B
    Future Oncol; 2021 Aug; 17(22):2883-2892. PubMed ID: 33858190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On variable selection in a semiparametric AFT mixture cure model.
    Parsa M; Taghavi-Shahri SM; Van Keilegom I
    Lifetime Data Anal; 2024 Apr; 30(2):472-500. PubMed ID: 38436831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of survival data with cure fraction and variable selection: A pseudo-observations approach.
    Su CL; Chiou SH; Lin FC; Platt RW
    Stat Methods Med Res; 2022 Nov; 31(11):2037-2053. PubMed ID: 35754373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Risk Factors for Relapse in Childhood Leukemia Using Penalized Semi-parametric Mixture Cure Competing Risks Model.
    Mehrbakhsh Z; Tapak L; Behnampour N; Roshanaei G
    J Res Health Sci; 2024 Jun; 24(2):e00615. PubMed ID: 39072551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
    Archer KJ; Fu H; Mrózek K; Nicolet D; Mims AS; Uy GL; Stock W; Byrd JC; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T; Eisfeld AK
    J Hematol Oncol; 2024 May; 17(1):28. PubMed ID: 38702786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False discovery control for penalized variable selections with high-dimensional covariates.
    He K; Zhou X; Jiang H; Wen X; Li Y
    Stat Appl Genet Mol Biol; 2018 Dec; 17(6):. PubMed ID: 30864387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cure rate models for heterogeneous competing causes.
    Brandão M; Leão J; Gallardo DI; Bourguignon M
    Stat Methods Med Res; 2023 Sep; 32(9):1823-1841. PubMed ID: 37489264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penalized Bayesian forward continuation ratio model with application to high-dimensional data with discrete survival outcomes.
    Seffernick AE; Archer KJ
    PLoS One; 2024; 19(3):e0300638. PubMed ID: 38547174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. geecure: An R-package for marginal proportional hazards mixture cure models.
    Niu Y; Wang X; Peng Y
    Comput Methods Programs Biomed; 2018 Jul; 161():115-124. PubMed ID: 29852954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penalized likelihood estimation of a mixture cure Cox model with partly interval censoring-An application to thin melanoma.
    Webb A; Ma J; Lô SN
    Stat Med; 2022 Jul; 41(17):3260-3280. PubMed ID: 35474515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable selection in semiparametric cure models based on penalized likelihood, with application to breast cancer clinical trials.
    Liu X; Peng Y; Tu D; Liang H
    Stat Med; 2012 Oct; 31(24):2882-91. PubMed ID: 22733695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder.
    Arano I; Sugimoto T; Hamasaki T; Ohno Y
    BMC Med Res Methodol; 2010 Apr; 10():33. PubMed ID: 20412598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional proportional hazards mixture cure model with applications in cancer mortality in NHANES and post ICU recovery.
    Ghosal R; Matabuena M; Zhang J
    Stat Methods Med Res; 2023 Nov; 32(11):2254-2269. PubMed ID: 37855203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable selection for mixture and promotion time cure rate models.
    Masud A; Tu W; Yu Z
    Stat Methods Med Res; 2018 Jul; 27(7):2185-2199. PubMed ID: 27856963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A frailty mixture cure model with application to hospital admission data [corrected].
    Yu B
    Biom J; 2008 Jun; 50(3):386-94. PubMed ID: 18217699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation method of the semiparametric mixture cure gamma frailty model.
    Peng Y; Zhang J
    Stat Med; 2008 Nov; 27(25):5177-94. PubMed ID: 18613271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of a Mixture Cure Rate Model based on the Generalized Modified Weibull Distribution for the Analysis of Leukemia Patients.
    Omer ME; Abu Bakar M; Adam M; Mustafa M
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1045-1053. PubMed ID: 33906295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling false discovery rate for mediator selection in high-dimensional data.
    Dai R; Li R; Lee S; Liu Y
    Biometrics; 2024 Jul; 80(3):. PubMed ID: 39073774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable selection in semiparametric nonmixture cure model with interval-censored failure time data: An application to the prostate cancer screening study.
    Sun L; Li S; Wang L; Song X
    Stat Med; 2019 Jul; 38(16):3026-3039. PubMed ID: 31032999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.